Blood serotonin concentration is thought to regulate behavior and may be implicated in the development of psychopathological symptoms as well. Serotonin transporter regulates the levels of serotonin by the reuptake of this neurotransmitter from the synaptic cleft. In this study we compare the platelet serotonin concentration and constant V(max) value in patients with schizophrenia and healthy controls with different 5-HTTLPR genotypes. The study included 60 patients and 62 controls. Biochemical parameters mentioned above were associated with a 5-HTTLPR genotype. Carriers of the LL genotype had lower serotonin blood concentration and V(max) compared to genotypes containing one or two copies of an S allele both in patients and controls. The results obtained suggest that the genetic variant may contribute to the state of serotoninergic system.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The effects of corticotropin-releasing factor (CRF) and urocortins on the serotonin (hydroxytryptamine, 5HT) released from the raphe nuclei (RN).
Neuropeptides
January 2025
Department of Pathophysiology, Faculty of Medicine, University of Szeged, Hungary.
Corticotropin-releasing factor (CRF) and urocortins (UCN1, UCN2 and UCN3) belong to the same CRF family of neuropeptides. They regulate the neuroendocrine, autonomic and behavioral responses to stress via two CRF receptors (CRF1 and CRF2). Stress, anxiety and depression affects the activity of the hypothalamic-pituitary-adrenal (HPA) axis and the serotoninergic neurotransmission, both being regulated by CRF and CRF-related peptides.
View Article and Find Full Text PDFFrom Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.
Int J Mol Sci
November 2024
Department of Psychiatry, "Carol Davila" University of Medicine and Pharmacy Bucharest, 020021 Bucharest, Romania.
Alzheimer's disease (AD) is a global health concern and the leading cause of dementia in the elderly. The prevalence of this neurodegenerative condition is projected to increase concomitantly with increased life expectancy, resulting in a significant economic burden. With very few FDA-approved disease-modifying drugs available for AD, there is an urgent need to develop new compounds capable of impeding the progression of the disease.
View Article and Find Full Text PDFA new pharmacological strategy against treatment-resistant depression.
Prog Neuropsychopharmacol Biol Psychiatry
November 2024
Departamento de Fisiología Humana, Facultad de Medicina, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Campus de Teatinos s/n, Málaga, Spain. Electronic address:
Major depressive disorder affects more than 50 million people in the world. However, 50% of patients don't respond to two or more drugs or psychotherapeutic treatments, named treatment-resistant depression (TRD). In this work, we propose a new augmentation treatment against TRD based on combining Fluoxetine (FLX) and the N-terminal fragment Galanin, GAL(1-15).
View Article and Find Full Text PDFEffects of lateral ventricle injection of 5,7-dihydroxytryptamine on neurons in the medial prefrontal cortex of rats: An electrophysiology study.
Neurosci Lett
January 2025
College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang 471023, China.
The medial prefrontal cortex (mPFC) is closely associated with various psychopathologies in humans, and its dysfunction is invariably accompanied by abnormalities in the serotonin (5-hydroxytryptamine, 5-HT) system of the brain. In this study, in-vivo extracellular recording techniques were used to investigate changes in the excitability of pyramidal neurons and interneurons in the rat mPFC following injection of 5,7-dihydroxytryptamine (5,7-DHT) into the bilateral lateral ventricles to damage the serotoninergic neurons. The levels of 5-HT in the mPFC and dorsal raphe nucleus of rats were determined by high-performance liquid chromatography.
View Article and Find Full Text PDFEffects of serotonergic manipulation in the brainstem and hypothalamus of overnourished rats during lactation.
Life Sci
December 2024
Postgraduate Program in Neuropsychiatry and Behavior Science, Federal University of Pernambuco - UFPE, Recife, PE, Brazil; Postgraduate Program in Biochemistry and Physiology, Federal University of Pernambuco -UFPE, Recife, PE, Brazil; Graduate Program in Nutrition, Physical Activity, and Phenotypic Plasticity, Federal University of Pernambuco-UFPE, Vitória de Santo Antão, PE, Brazil. Electronic address:
Article Synopsis
- Previous research indicates that being overweight or obese can disrupt brain function during critical developmental phases, but more studies are needed on how immediate overnutrition affects serotonin in the brain.
- This study investigates how altering serotonin levels with fluoxetine treatment in overnourished rats impacts oxidative stress and inflammatory markers in their brainstem and hypothalamus.
- Findings suggest that overnutrition in early life leads to harmful changes in brain chemistry, but fluoxetine treatment can counteract some of these negative effects, supporting healthier brain development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!